Verve Therapeutics Inc (VERV)
4.835
-0.54
(-10.13%)
USD |
NASDAQ |
Nov 15, 15:33
Verve Therapeutics Research and Development Expense (Quarterly): 49.94M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 49.94M |
| June 30, 2024 | 50.98M |
| March 31, 2024 | 48.38M |
| December 31, 2023 | 46.81M |
| September 30, 2023 | 43.76M |
| June 30, 2023 | 47.26M |
| March 31, 2023 | 47.11M |
| December 31, 2022 | 37.28M |
| September 30, 2022 | 35.20M |
| June 30, 2022 | 33.12M |
| Date | Value |
|---|---|
| March 31, 2022 | 24.49M |
| December 31, 2021 | 25.94M |
| September 30, 2021 | 17.50M |
| June 30, 2021 | 13.42M |
| March 31, 2021 | 11.34M |
| December 31, 2020 | 15.58M |
| September 30, 2020 | 7.618M |
| June 30, 2020 | 5.654M |
| March 31, 2020 | 6.523M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.654M
Minimum
Jun 2020
50.98M
Maximum
Jun 2024
29.89M
Average
33.12M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Ardelyx Inc | 15.31M |
| Biomarin Pharmaceutical Inc | 184.90M |
| Sage Therapeutics Inc | 54.58M |
| ALX Oncology Holdings Inc | 26.47M |
| Immuneering Corp | 10.65M |